Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: Two phase 3, multicenter, randomized, double-blind, placebo-controlled studies

Journal of Drugs in Dermatology

Volumn 13, Issue 2, 2014, Pages 166-169

  Swanson, Neil ^a   Smith, Christina Cognata ^b   Kaur, Mandeep ^b   Goldenberg, Gary ^c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Division of Valeant Pharmaceuticals   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD; PLACEBO;

ACTINIC KERATOSIS; ADULT; ARTICLE; CLINICAL LABORATORY; CONTROLLED STUDY; CREAM; DISEASE CLEARANCE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; LABORATORY TEST; LOCAL SKIN REACTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADJUVANTS, IMMUNOLOGIC; ADULT; AMINOQUINOLINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FACE; FEMALE; HUMANS; KERATOSIS, ACTINIC; MALE; MIDDLE AGED; SCALP; SKIN AGING; TREATMENT OUTCOME;

EID: 84896336368     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Fleischer AB Jr, Herbert CR, Feldman SR, et al. Diagnosis of skin disease by nondermatologists. Am J Manag Care 2000;6:1149-1156.
2. Berman B, Bienstock L, Kuritzky L, et al. Actinic keratoses: sequelae and treatments. Recommendations from a consensus panel. J Fam Pract 2006;55(Suppl):1-8.
3. Warino L, Tusa M, Camacho F, et al. Frequency and cost of actinic keratosis treatment. Dermatol Surg 2006;32:1045-1049. (Pubitemid 44197455)
4. Frost CA, Green AC. Epidemiology of solar keratoses. Br J Dermatol 1994;131:455-464. (Pubitemid 24315411)
5. Harvey I, Frankel S, Marks R, et al. Non-melanoma skin cancer and solar keratoses, II: analytical results of the South Wales skin cancer study. Br J Cancer 1996; 74:1308-1312. (Pubitemid 26360125)
6. Harvey I, Frankel S, Marks R, et al. Non-melanoma skin cancer and solar keratoses, II: analytical results of the South Wales skin cancer study. Br J Cancer 1996; 74:1308-1312. (Pubitemid 26360125)
7. Zagula-Mally ZW, Rosenberg EW, Kashgarian M. Frequency of skin cancer and solar keratoses in a rural southern county as determined by population sampling. Cancer 1974;34:345-349.
8. Marks R, Foley P, Goodman G, et al. Spontaneous remission of solar keratoses: the case for conservative management. Br J Dermatol 1986;115:649-655. (Pubitemid 17181888)
9. Stockfleth E, Kerl H. Guideline Subcommittee of the European Dermatology Forum. Guidelines for the management of actinic keratoses. Eur J Dermatol 2006;16:599-606.
10. Criscione VD, Weinstock MA, Naylor MF, et al.Actinic keratosis: natural history and risk of malignant transformation in the Vtererans Affairs topical tretinoin chemoprevention trial. Cancer 2009;115(11):2523-2530.
11. Hadley G, Derry S, Moore, RA. Imiquimod for actinic keratosis: systemic review and meta-analysis. J Invest Dermatol 2006;126:1251-1255. (Pubitemid 43997904)
12. Carroll CL, Feldman SR, Camacho FT, et al. Adherence to topical therapy decreases during the course of an 8-week psoriasis clinical trial: commonly used methods of measuring adherence to topical therapy overestimate actual use. J Am Acad Dermatol 2004;51:212-216.
13. Gebauer K, Shumack S, Cowen PSJ. Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, placebo-controlled study. Br J Dermatol 2009;161:897-903.
14. Swanson N, Abramovits W, Berman B, et al. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: Results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol 2010;62(4):582-590.
15. Hanke CW, Beer KR, Stockfleth E, et al. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: Results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles. J Am Acad Dermatol 2010;62(4): 573-581.
16. Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 2004;50:714-721. (Pubitemid 38580548)
17. Jorizzo J, Dinehart S, Matheson R, et al. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol 2007;57:265-268. (Pubitemid 47048863)
18. Salasche SJ, Levine N, Morrison L. Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: an open-label trial. J Am Acad Dermatol 2002;47: 571-577.